Infection, Sepsis
Conditions
Brief summary
This study is a prospective, single center, observational, cohort study of patients to determine whether the Mologic Biomarker Panel can identify patients with infection from those without, including those with other reasons for inflammation (e.g. post-operative). It will also assess whether it has the potential to judge the severity of illness, prognosticate outcome and guide antibiotic therapy. The aim is to recruit patients who are representative of patients with suspected sepsis, uncomplicated infection, or non-infection related critical illness that require critical care intervention and assessment. This study is observational and will not alter patient management or the standard of care. The results from the investigational Mologic Biomarker Panel and associated research assays will not be provided to treating clinicians, or used in any manner to affect patient care. The study will take place over approximately an 18-month period and it is anticipated that approximately 600 patients will be collectively enrolled. The study aims to recruit patients from three environments within UCLH: * The Emergency Department. * Critical Care Unit * Patients undergoing major surgery
Interventions
DIAGNOSTIC_TESTMologic Biomarker Panel
In brief the proposed biomarkers will be measured in the laboratory of Mologic . These will initially be performed using standard lab assays (Enzyme Linked Immunosorbent Assays, ELISA). Biomarkers that show promise will then be mounted on a novel lateral flow device (under development), that could ultimately be deployed at the patients bedside.
Sponsors
University College London Hospitals
Innovate UK
Mologic Ltd
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* ≥ 18 years old * Investigated for potential infection (the clinical need for a blood culture)
Exclusion criteria
* \<18 years old * Severe anaemia (\<60g/dl) and contra-indication to transfusion * Unable to gain consent or agreement * Treated with palliative intent * Blood culture indicated for screening or monitoring
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Biomarkers and results from routine clinical testing for infection | 18 months | Research assay will be used to test for the investigational Mologic biomarker panel and these results will be assessed using the results obtained from conventional testing used to identify infection (such as white cell count and CRP), in order to find a clinical association with the mologic biomarkers and patients with infections. |
Countries
United Kingdom
Contacts
Primary ContactChris Dunston, PhD
Backup ContactJohn Wilkins, PhD
Outcome results
None listed